Literature DB >> 22155099

Berberine ameliorates COX-2 expression in rat small intestinal mucosa partially through PPARγ pathway during acute endotoxemia.

Ai-Wen Feng1, Wei Gao, Guang-Rong Zhou, Ren Yu, Ning Li, Xin-Li Huang, Qiu-Rong Li, Jie-Shou Li.   

Abstract

Berberine hydrochloride (BBR), a plant alkaloid, has been used to treat intestinal inflammation or infection for years. Cyclooxygenase-2 (COX-2) is pro-inflammatory mediator and involved in the induction of gut inflammation. The expression of COX-2 in small bowel mucosa was determined and the mechanism by which BBR modulated COX-2 expression was explored in a rat model of endotoxemia induced by lipopolysaccharide (LPS). The results showed that without LPS stimulation COX-2 was constitutively expressed at low levels in control rats. LPS challenge rapidly induced COX-2 gene transcription resulting in high levels of inducible COX-2 expression in endotoxemic rats. BBR pre- and post-treatment had no marked effect on constitutive COX-2 expression but inhibited inducible COX-2 overexpression. LPS challenge increased the expression and phosphorylation of peroxisome proliferator-activated receptor gamma (PPARγ), p38 and activating transcription factor 2 and 3 (ATF2, ATF3), but the effects of LPS were inhibited by BBR treatment. GW9662 did not influence constitutive COX-2 expression but enhanced inducible COX-2 overproduction. Besides, GW9662 abolished the inhibitory effect of BBR on inducible COX-2, p38, ATF2, 3 expression and phosphorylation. Collectively, these results indicated that BBR gavage could attenuate the overexpression of inducible COX-2, not constitutive COX-2, in ileal mucosa during acute endotoxemia in part via activation of PPARγ pathway, which negatively interfered with p38/ATFs cascade.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22155099     DOI: 10.1016/j.intimp.2011.11.009

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  20 in total

1.  Characterization and evolution of intestine injury at the anhepatic phase in portal hypertensive rats.

Authors:  Guijun Ren; Xiaoye Yuan; Xin Zhao; Qingchun Hao; Jinglin Cao; Yang Wang; Qingjun Gao; Jian Dou; Qiang Zeng
Journal:  Exp Ther Med       Date:  2018-09-27       Impact factor: 2.447

2.  The effect of Hangeshashinto on Oral Mucositis Caused by Induction Chemotherapy in Patients with Head and Neck Cancer.

Authors:  Kenkichiro Taira; Kazunori Fujiwara; Takahiro Fukuhara; Satoshi Koyama; Hiromi Takeuchi
Journal:  Yonago Acta Med       Date:  2020-08-20       Impact factor: 1.641

3.  Berberine mitigates cyclophosphamide-induced hepatotoxicity by modulating antioxidant status and inflammatory cytokines.

Authors:  Mousa O Germoush; Ayman M Mahmoud
Journal:  J Cancer Res Clin Oncol       Date:  2014-04-18       Impact factor: 4.553

4.  The clinical impact of Hangeshashinto (TJ-14) in the treatment of chemotherapy-induced oral mucositis in gastric cancer and colorectal cancer: Analyses of pooled data from two phase II randomized clinical trials (HANGESHA-G and HANGESHA-C).

Authors:  Kazuhiro Nishikawa; Toru Aoyama; Mari S Oba; Takaki Yoshikawa; Chu Matsuda; Yoshinori Munemoto; Nobuhiro Takiguchi; Kazuaki Tanabe; Naoki Nagata; Motohiro Imano; Mitsuru Oshiro; Ryoji Fukushima; Masato Kataoka; Satoshi Morita; Akira Tsuburaya; Hideyuki Mishima; Toru Kono; Junichi Sakamoto
Journal:  J Cancer       Date:  2018-04-19       Impact factor: 4.207

5.  Berberine protects human renal proximal tubular cells from hypoxia/reoxygenation injury via inhibiting endoplasmic reticulum and mitochondrial stress pathways.

Authors:  Wenli Yu; Mingwei Sheng; Rubin Xu; Jianjian Yu; Kang Cui; Jingkai Tong; Liying Shi; Hengchang Ren; Hongyin Du
Journal:  J Transl Med       Date:  2013-01-29       Impact factor: 5.531

6.  Update on berberine in nonalcoholic Fatty liver disease.

Authors:  Yang Liu; Li Zhang; Haiyan Song; Guang Ji
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-17       Impact factor: 2.629

Review 7.  Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus.

Authors:  Zheng Li; Ya-Na Geng; Jian-Dong Jiang; Wei-Jia Kong
Journal:  Evid Based Complement Alternat Med       Date:  2014-02-11       Impact factor: 2.629

8.  Double-blind, placebo-controlled, randomized phase II study of TJ-14 (hangeshashinto) for gastric cancer chemotherapy-induced oral mucositis.

Authors:  Toru Aoyama; Kazuhiro Nishikawa; Nobuhiro Takiguchi; Kazuaki Tanabe; Motohiro Imano; Ryoji Fukushima; Junichi Sakamoto; Mari S Oba; Satoshi Morita; Toru Kono; Akira Tsuburaya
Journal:  Cancer Chemother Pharmacol       Date:  2014-03-21       Impact factor: 3.333

Review 9.  Phytochemical Compounds and Protection from Cardiovascular Diseases: A State of the Art.

Authors:  Beniamino Pagliaro; Caterina Santolamazza; Francesca Simonelli; Speranza Rubattu
Journal:  Biomed Res Int       Date:  2015-10-04       Impact factor: 3.411

10.  Berberine improves the intestinal antioxidant status of laboratory mice, Mus musculus.

Authors:  Mohamed A Dkhil; Mahmoud S Metwaly; Saleh Al-Quraishy
Journal:  Saudi J Biol Sci       Date:  2015-10-24       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.